Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer


Jul 19 2022 • 35 mins


Listen to gynaecologic oncology specialists Prof. Nicoletta Colombo and Dr Natalia R Gómez-Hidalgo discuss three key topics relating to PARP inhibitors in the first-line maintenance setting for advanced ovarian cancer – rationale for use, which patients may particularly benefit, and key factors informing PARP inhibitor selection.

Discussion on these themes is based on questions posed by healthcare professionals involved in the care of patients with ovarian cancer.

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from GlaxoSmithKline. This medical education is provided by touchIME.

For further information visit our website: